Human immunodeficiency virus (HIV) infection is an established risk factor for pulmonary
arterial hypertension (PAH); however, the pathogenesis of HIV-related PAH remains …

Human immunodeficiency virus (HIV)-associated pulmonary arterial hypertension (PAH) is a
serious noninfectious disease involving an aberrant increase in pressure in the blood …

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased
pulmonary arterial resistance and vessel remodeling. Patients living with human …

With the advent of anti-retroviral therapy, non-AIDS-related comorbidities have increased in
people living with HIV. Among these comorbidities, pulmonary hypertension (PH) is one of …

Pulmonary arterial hypertension (PAH) is increased in HIV, but its pathogenesis is not fully
understood. Nonhuman primates infected with simian immunodeficiency virus (SIV) or SIV …

Human immunodeficiency virus (HIV)–associated pulmonary arterial hypertension (PAH) is
a devastating, noninfectious complication of acquired immune deficiency syndrome, and the …

HIV-related pulmonary arterial hypertension (PAH) is one of the long-term complications of
HIV infection that has become increasingly apparent in recent years. The clinical …

Although overall survival rates of patients infected with human immunodeficiency virus (HIV)
have been significantly improved by antiretroviral therapy (ART), chronic comorbidities …

Pulmonary arterial hypertension (PAH) is a life-threatening disease with higher incidence in
HIV-infected compared with noninfected patients. SIV-infected NHP develop clinical …

Infection with HIV increases the risk for lung diseases, including noninfectious pulmonary
hypertension (PH). HIV-associated PH (HIV-PH) is an important lung disease in HIV-infected …